Birchview Capital’s Halozyme HALO Stock Holding History

Birchview Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$653K	Hold	10,100	–	–	0.37%	49
2025 Q4	$680K	Hold	10,100	–	–	0.4%	48
2025 Q3	$741K	Buy	10,100 +100	+1%	+$6.64K	0.56%	42
2025 Q2	$520K	Hold	10,000	–	–	0.52%	43
2025 Q1	$638K	Hold	10,000	–	–	0.55%	29
2024 Q4	$478K	Hold	10,000	–	–	0.39%	34
2024 Q3	$572K	Hold	10,000	–	–	0.5%	27
2024 Q2	$524K	Hold	10,000	–	–	0.48%	32
2024 Q1	$407K	Hold	10,000	–	–	0.33%	40
2023 Q4	$370K	Hold	10,000	–	–	0.29%	39
2023 Q3	$382K	Hold	10,000	–	–	0.32%	36
2023 Q2	$361K	Hold	10,000	–	–	0.27%	41
2023 Q1	$382K	Hold	10,000	–	–	0.3%	36
2022 Q4	$569K	Buy	+10,000	New	+$512K	0.4%	30

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital's HALO Position: Q1 2026 in Review

Birchview Capital held its Halozyme (HALO) position steady in Q1 2026 at 10,100 shares worth $653K. The position accounts for 0.37% of the portfolio, ranked #49.

Birchview Capital first reported a position in HALO in Q4 2022 and has held it in 14 quarters since. The position peaked at $741K in Q3 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

Birchview Capital held 10,100 shares of Halozyme worth $653K as of Q1 2026.
Birchview Capital left its Halozyme share count unchanged in Q1 2026.
Halozyme made up 0.37% of Birchview Capital's portfolio in Q1 2026, its #49 holding.
Birchview Capital first reported a position in Halozyme in Q4 2022 and has held it in 14 quarters since.
Birchview Capital's Halozyme position peaked at $741K in Q3 2025.
634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.